BRAF mutation is a significant genetic alteration in thyroid cancer, particularly in papillary thyroid cancer (PTC), occurring in about 45% of cases. It is mutually exclusive with other common genetic alterations like RET/PTC rearrangements and is associated with more aggressive subtypes of PTC, such as tall-cell PTC. The T1799A BRAF mutation is a specific diagnostic marker for PTC and is linked to poorer clinical outcomes. It is also a novel independent molecular prognostic marker. BRAF mutation is associated with increased risk of lymph node metastasis, advanced tumor stages, and cancer recurrence. It is mutually exclusive with RET/PTC rearrangements and shows a reciprocal age association with them. BRAF mutation is more prevalent in adults and is a major somatic genetic alteration driving PTC in this population, while RET/PTC is more common in children. BRAF mutation detection in FNAB specimens is highly specific for PTC and can aid in diagnosis. It is also a prognostic factor, predicting worse outcomes in PTC. Inhibiting the MAP kinase pathway, which is activated by BRAF mutation, is a promising therapeutic approach for thyroid cancer. Novel inhibitors targeting this pathway are being investigated for their potential in treating thyroid cancer.BRAF mutation is a significant genetic alteration in thyroid cancer, particularly in papillary thyroid cancer (PTC), occurring in about 45% of cases. It is mutually exclusive with other common genetic alterations like RET/PTC rearrangements and is associated with more aggressive subtypes of PTC, such as tall-cell PTC. The T1799A BRAF mutation is a specific diagnostic marker for PTC and is linked to poorer clinical outcomes. It is also a novel independent molecular prognostic marker. BRAF mutation is associated with increased risk of lymph node metastasis, advanced tumor stages, and cancer recurrence. It is mutually exclusive with RET/PTC rearrangements and shows a reciprocal age association with them. BRAF mutation is more prevalent in adults and is a major somatic genetic alteration driving PTC in this population, while RET/PTC is more common in children. BRAF mutation detection in FNAB specimens is highly specific for PTC and can aid in diagnosis. It is also a prognostic factor, predicting worse outcomes in PTC. Inhibiting the MAP kinase pathway, which is activated by BRAF mutation, is a promising therapeutic approach for thyroid cancer. Novel inhibitors targeting this pathway are being investigated for their potential in treating thyroid cancer.